Gene · 2213
Papers4,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,261 to 1,280 of 4,232
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. | J Immunother Cancer | 2021 | 34330764 | PubTator, text mining | PubMed |
| Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy? | Clin Microbiol Infect | 2021 | 34325068 | PubTator, text mining | PubMed |
| Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. | Blood Adv | 2021 | 34323958 | PubTator, text mining | PubMed |
| Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. | Blood Adv | 2021 | 34323957 | PubTator, text mining | PubMed |
| Fcγ receptor activation mediates vascular inflammation and abdominal aortic aneurysm development. | Clin Transl Med | 2021 | 34323424 | PubTator, text mining | PubMed |
| Sexual dimorphism of monocyte transcriptome in individuals with chronic low-grade inflammation. | Biol Sex Differ | 2021 | 34321081 | PubTator, text mining | PubMed |
| Age-related increase in caveolin-1 expression facilitates cell-to-cell transmission of α-synuclein in neurons. | Mol Brain | 2021 | 34321069 | PubTator, text mining | PubMed |
| Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. | MAbs | 2021 | 34313545 | PubTator, text mining | PubMed |
| Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. | MAbs | 2021 | 34313527 | PubTator, text mining | PubMed |
| Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy. | Front Immunol | 2021 | 34305927 | PubTator, text mining | PubMed |
| Antigen Loss after Targeted Immunotherapy in Hematological Malignancies. | Clin Lab Med | 2021 | 34304769 | PubTator, text mining | PubMed |
| Antibody-independent functions of B cells during viral infections. | PLoS Pathog | 2021 | 34293057 | PubTator, text mining | PubMed |
| Oral Versus Gastrointestinal Mucosal Immune Niches in Homeostasis and Allostasis. | Front Immunol | 2021 | 34290715 | PubTator, text mining | PubMed |
| Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis. | Front Pharmacol | 2021 | 34290613 | PubTator, text mining | PubMed |
| Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. | Front Pharmacol | 2021 | 34290608 | PubTator, text mining | PubMed |
| Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. | J Virol | 2021 | 34287040 | PubTator, text mining | PubMed |
| Latest impact of engineered human liver platforms on drug development. | APL Bioeng | 2021 | 34286173 | PubTator, text mining | PubMed |
| FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma. | Biomed Res Int | 2021 | 34285919 | PubTator, text mining | PubMed |
| Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer. | Onco Targets Ther | 2021 | 34285507 | PubTator, text mining | PubMed |
| scDPN for High-throughput Single-cell CNV Detection to Uncover Clonal Evolution During HCC Recurrence. | Genomics Proteomics Bioinformatics | 2021 | 34280548 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2213/papers?page=64